Data as of Dec 06
| -0.17 / -7.66%|
Athersys, Inc. operates as a clinical stage biopharmaceutical company, which is focused primarily in the field of regenerative medicine. It engages in the discovery and development of best-in-class therapies designed to extend and enhance the quality of human life. The company's product development portfolio consists of MultiStem, which is a patented and proprietary stem cell product, which enhances tissue repair and healing in multiple ways including, reducing inflammatory damage, protecting tissue that is at risk following acute or ischemic injury, and promoting formation of new blood vessels in regions of ischemic injury. Its current clinical development programs are focused on treating inflammatory disorders, neurological conditions, cardiovascular disease, and other conditions. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.
|Gil van Bokkelen||Chairman & Chief Executive Officer|
|William B. J. Lehmann||President, Chief Operating Officer & Secretary|
|Laura K. Campbell||Vice President-Finance|
|John J. Harrington||Director, Chief Scientific Officer & Executive VP|
|Manal Morsy||Vice President & Head-Global Regulatory Affairs|